Epigenetics Market Intelligence Report 2026: Strong Demand from Oncology, Precision Medicine, Pharmaceutical Research, and Liquid-Biopsy Development
The global epigenetics market is estimated at USD 2.70 billion in 2025 and projected to reach USD 8.30 billion by 2034, expanding at a CAGR of 13.3%. Growth is driven by rising cancer burden, precision medicine adoption, liquid-biopsy development, and advances in sequencing technologies. DNA methylation dominates the technology segment at 48% market share, while kits and reagents lead products at 41%. Oncology represents the largest application at 60%, with pharmaceutical and biotech companies as the primary end-users at 44% market share. North America leads with 43% global revenue, while Asia-Pacific is the fastest-growing region.